Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
100.5 EUR | +1.31% | +1.62% | +6.52% |
Apr. 22 | GERRESHEIMER AG : Buy rating from Barclays | ZD |
Apr. 22 | GERRESHEIMER AG : Jefferies remains its Buy rating | ZD |
Summary
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company is in debt and has limited leeway for investment
- The firm trades with high earnings multiples: 24.27 times its 2024 earnings per share.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+6.52% | 3.71B | B+ | ||
-2.31% | 187B | C+ | ||
-3.20% | 106B | C | ||
-5.04% | 66.9B | A | ||
+0.20% | 49.45B | B- | ||
+17.29% | 48B | B- | ||
+4.06% | 40.84B | B+ | ||
+2.07% | 26.48B | B | ||
+2.36% | 26.25B | A- | ||
+12.96% | 24.62B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- GXI Stock
- Ratings Gerresheimer AG